Chemours price target raised to $20 from $18 at BMO Capital

Core Viewpoint - BMO Capital analyst John McNulty raised the price target for Chemours (CC) to $20 from $18, maintaining an Outperform rating after the company sold its Taiwan TiO2 site for $360 million, which is seen as a significant positive development for Chemours [1] Group 1: Financial Impact - The sale of the Taiwan TiO2 site for $360 million is described as a "sizable windfall" for Chemours [1] - Proceeds from the sale are expected to be used for debt reduction, providing a "liquidity cushion" for future PFAS settlements [1] - The firm anticipates that the sale will help investors feel more comfortable about Chemours' cash position to fund future growth opportunities [1]